211 related articles for article (PubMed ID: 34789076)
21. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis.
Pectasides D; Mylonakis A; Varthalitis J; Kostopoulou M; Constantinou A; Papazachariou K; Antoniou F; Dimitriadis M; Athanassiou A
Oncology; 1997; 54(1):1-6. PubMed ID: 8978584
[TBL] [Abstract][Full Text] [Related]
22. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
23. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
Olver I; Paska W; Depierre A; Seitz JF; Stewart DJ; Goedhals L; McQuade B; McRae J; Wilkinson JR
Ann Oncol; 1996 Nov; 7(9):945-52. PubMed ID: 9006746
[TBL] [Abstract][Full Text] [Related]
24. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
Tanimura S; Banba J; Tomoyasu H; Masaki M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
[TBL] [Abstract][Full Text] [Related]
25. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
26. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
Hesketh PJ; Grunberg SM; Gralla RJ; Warr DG; Roila F; de Wit R; Chawla SP; Carides AD; Ianus J; Elmer ME; Evans JK; Beck K; Reines S; Horgan KJ;
J Clin Oncol; 2003 Nov; 21(22):4112-9. PubMed ID: 14559886
[TBL] [Abstract][Full Text] [Related]
27. [Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin].
Harousseau JL
Bull Cancer; 1996 Jan; 83(1):71-76. PubMed ID: 8672859
[TBL] [Abstract][Full Text] [Related]
28. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
[TBL] [Abstract][Full Text] [Related]
29. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.
Holdsworth MT; Raisch DW; Duncan MH; Chavez CM; Leasure MM
Ann Pharmacother; 1995 Jan; 29(1):16-21. PubMed ID: 7711340
[TBL] [Abstract][Full Text] [Related]
30. Reduced maintenance of complete protection from emesis for women during chemotherapy cycles.
Liaw CC; Chang HK; Liau CT; Huang JS; Lin YC; Chen JS
Am J Clin Oncol; 2003 Feb; 26(1):12-5. PubMed ID: 12576917
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Depierre A
Bull Cancer; 1996 Feb; 83(2):147-53. PubMed ID: 8652909
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
33. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
34. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
35. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.
Herrstedt J; Summers Y; Jordan K; von Pawel J; Jakobsen AH; Ewertz M; Chan S; Naik JD; Karthaus M; Dubey S; Davis R; Fox GM
Support Care Cancer; 2019 Jul; 27(7):2699-2705. PubMed ID: 30488222
[TBL] [Abstract][Full Text] [Related]
36. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
Cocquyt V; Van Belle S; Reinhardt RR; Decramer ML; O'Brien M; Schellens JH; Borms M; Verbeke L; Van Aelst F; De Smet M; Carides AD; Eldridge K; Gertz BJ
Eur J Cancer; 2001 May; 37(7):835-42. PubMed ID: 11313170
[TBL] [Abstract][Full Text] [Related]
37. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Bacchi M; Buser K; Kirchner V; Neuenschwander H; Orth B; Aapro MS; Thürlimann B
Ann Oncol; 1994 Mar; 5(3):253-8. PubMed ID: 8186174
[TBL] [Abstract][Full Text] [Related]
38. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
39. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
[TBL] [Abstract][Full Text] [Related]
40. Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
Hesketh PJ; Warr DG; Street JC; Carides AD
Support Care Cancer; 2011 Sep; 19(9):1297-302. PubMed ID: 20623144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
